Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.

中文翻译：

---

人工智能和内组织组学：炎症性肠病精密内窥镜和组织学的新维度


将人工智能融入炎症性肠病（IBD）有可能彻底改变临床实践和研究。人工智能利用先进的算法对 IBD 内窥镜检查和组织学进行准确评估，从而提供对疾病活动性、标准化评分和结果预测的精确评估。此外，人工智能通过交织和协调内窥镜检查、组织学和组学数据以实现精准医学，为整体内组织组学方法提供了潜力。人工智能的新兴应用可以为 IBD 的个性化医疗铺平道路，为患者提供分层，以最小的风险获得最有益的治疗。尽管人工智能前景广阔，但挑战仍然存在，包括数据质量、标准化、可重复性、随机对照试验的稀缺性、临床实施、伦理问题、法律责任和监管问题。制定标准化指南和跨学科合作（包括政策制定者和监管机构）对于应对这些挑战并推进 IBD 临床实践和试验中的人工智能至关重要。